113 related articles for article (PubMed ID: 31145622)
1. Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.
Hou W; Sun H; Ma Y; Liu C; Zhang Z
J Med Chem; 2019 Jun; 62(12):5901-5919. PubMed ID: 31145622
[TBL] [Abstract][Full Text] [Related]
2. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
3. Discovery and
Chen X; Yan Y; Zhang Z; Zhang F; Liu M; Du L; Zhang H; Shen X; Zhao D; Shi JB; Liu X
J Med Chem; 2021 Aug; 64(16):11857-11885. PubMed ID: 34374541
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C.
Korkmaz B; Lesner A; Wysocka M; Gieldon A; Håkansson M; Gauthier F; Logan DT; Jenne DE; Lauritzen C; Pedersen J
Biochem Pharmacol; 2019 Jun; 164():349-367. PubMed ID: 30978322
[TBL] [Abstract][Full Text] [Related]
5. BI 1291583: a novel selective inhibitor of cathepsin C with superior in vivo profile for the treatment of bronchiectasis.
Kreideweiss S; Schänzle G; Schnapp G; Vintonyak V; Grundl MA
Inflamm Res; 2023 Aug; 72(8):1709-1717. PubMed ID: 37542002
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).
Doyle K; Lönn H; Käck H; Van de Poël A; Swallow S; Gardiner P; Connolly S; Root J; Wikell C; Dahl G; Stenvall K; Johannesson P
J Med Chem; 2016 Oct; 59(20):9457-9472. PubMed ID: 27690432
[TBL] [Abstract][Full Text] [Related]
8. Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases.
Guarino C; Hamon Y; Croix C; Lamort AS; Dallet-Choisy S; Marchand-Adam S; Lesner A; Baranek T; Viaud-Massuard MC; Lauritzen C; Pedersen J; Heuzé-Vourc'h N; Si-Tahar M; Fıratlı E; Jenne DE; Gauthier F; Horwitz MS; Borregaard N; Korkmaz B
Biochem Pharmacol; 2017 May; 131():52-67. PubMed ID: 28193451
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.
Wang Y; Chen Z; Dai M; Sun P; Wang C; Gao Y; Zhao H; Zeng W; Shen L; Mao W; Wang T; Hu G; Li J; Chen S; Long C; Chen X; Liu J; Zhang Y
Bioorg Med Chem Lett; 2017 Jun; 27(11):2420-2423. PubMed ID: 28433531
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin C inhibition as a potential treatment strategy in cancer.
Korkmaz B; Lamort AS; Domain R; Beauvillain C; Gieldon A; Yildirim AÖ; Stathopoulos GT; Rhimi M; Jenne DE; Kettritz R
Biochem Pharmacol; 2021 Dec; 194():114803. PubMed ID: 34678221
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin C inhibitors: property optimization and identification of a clinical candidate.
Furber M; Tiden AK; Gardiner P; Mete A; Ford R; Millichip I; Stein L; Mather A; Kinchin E; Luckhurst C; Barber S; Cage P; Sanganee H; Austin R; Chohan K; Beri R; Thong B; Wallace A; Oreffo V; Hutchinson R; Harper S; Debreczeni J; Breed J; Wissler L; Edman K
J Med Chem; 2014 Mar; 57(6):2357-67. PubMed ID: 24592859
[TBL] [Abstract][Full Text] [Related]
12. Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?
Korkmaz B; Lesner A; Marchand-Adam S; Moss C; Jenne DE
J Med Chem; 2020 Nov; 63(22):13258-13265. PubMed ID: 32692176
[TBL] [Abstract][Full Text] [Related]
13. In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C.
Méthot N; Guay D; Rubin J; Ethier D; Ortega K; Wong S; Normandin D; Beaulieu C; Reddy TJ; Riendeau D; Percival MD
Mol Pharmacol; 2008 Jun; 73(6):1857-65. PubMed ID: 18326050
[TBL] [Abstract][Full Text] [Related]
14. Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
Planken S; Behenna DC; Nair SK; Johnson TO; Nagata A; Almaden C; Bailey S; Ballard TE; Bernier L; Cheng H; Cho-Schultz S; Dalvie D; Deal JG; Dinh DM; Edwards MP; Ferre RA; Gajiwala KS; Hemkens M; Kania RS; Kath JC; Matthews J; Murray BW; Niessen S; Orr ST; Pairish M; Sach NW; Shen H; Shi M; Solowiej J; Tran K; Tseng E; Vicini P; Wang Y; Weinrich SL; Zhou R; Zientek M; Liu L; Luo Y; Xin S; Zhang C; Lafontaine J
J Med Chem; 2017 Apr; 60(7):3002-3019. PubMed ID: 28287730
[TBL] [Abstract][Full Text] [Related]
15. Functional studies of Plasmodium falciparum dipeptidyl aminopeptidase I using small molecule inhibitors and active site probes.
Deu E; Leyva MJ; Albrow VE; Rice MJ; Ellman JA; Bogyo M
Chem Biol; 2010 Aug; 17(8):808-19. PubMed ID: 20797610
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of cathepsin C: from pathophysiology to treatment.
Korkmaz B; Caughey GH; Chapple I; Gauthier F; Hirschfeld J; Jenne DE; Kettritz R; Lalmanach G; Lamort AS; Lauritzen C; Łȩgowska M; Lesner A; Marchand-Adam S; McKaig SJ; Moss C; Pedersen J; Roberts H; Schreiber A; Seren S; Thakker NS
Pharmacol Ther; 2018 Oct; 190():202-236. PubMed ID: 29842917
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors.
Romu AA; Lei Z; Zhou B; Chen ZS; Korlipara V
Bioorg Med Chem Lett; 2017 Nov; 27(21):4832-4837. PubMed ID: 28974338
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic utility and medicinal chemistry of cathepsin C inhibitors.
Guay D; Beaulieu C; Percival MD
Curr Top Med Chem; 2010; 10(7):708-16. PubMed ID: 20337582
[TBL] [Abstract][Full Text] [Related]
20. E-64c-hydrazide: a lead structure for the development of irreversible cathepsin C inhibitors.
Radzey H; Rethmeier M; Klimpel D; Grundhuber M; Sommerhoff CP; Schaschke N
ChemMedChem; 2013 Aug; 8(8):1314-21. PubMed ID: 23780739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
